logo-loader
CytoDyn

CytoDyn armed with 'key test' to guide its near-term discussions with the FDA

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive Investors the late-stage biotechnology company developing leronlimab (PRO 140) as a monotherapy for HIV patients has completed a key test will would “guide” discussions with the FDA on leronlimab as a single treatment for HIV.

Dr. Pourhassan says the company has completed a diagnostic test, called a Receptor Occupancy Test, as a measure for more precise screening for leronlimab monotherapy.

Quick facts: CytoDyn

Price: $0.43

Market: OTCQB
Market Cap: $162.01 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn sees 'strong result' in leronlimab dose escalation...

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive the biotech's HIV monotherapy dose escalating trial with its flagship drug leronlimab (PRO 140) topped expectations. Dr Pourhassan says patients receiving 525 mg achieved a 'strong result' with a 94% response rate. 

1 week, 3 days ago

2 min read